Growing community of inventors

Rijen, Netherlands

Niels Hoogenboom

Average Co-Inventor Count = 5.83

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 6

Niels HoogenboomTjeerd Barf (4 patents)Niels HoogenboomAllard Kaptein (2 patents)Niels HoogenboomArthur A Oubrie (2 patents)Niels HoogenboomSander De Wilde (2 patents)Niels HoogenboomEduard Willem Zwart (2 patents)Niels HoogenboomEdwin De Zwart (2 patents)Niels HoogenboomSaskia Verkaik (2 patents)Niels HoogenboomDennis Demont (2 patents)Niels HoogenboomCarsten Schultz-Fademrecht (1 patent)Niels HoogenboomCarsten Schultz-Fadermrecht (1 patent)Niels HoogenboomCarsten Schultz - Fademrecht (0 patent)Niels HoogenboomTjeerd Andries Barf (0 patent)Niels HoogenboomSander Martijn De Wilde (0 patent)Niels HoogenboomNiels Hoogenboom (4 patents)Tjeerd BarfTjeerd Barf (23 patents)Allard KapteinAllard Kaptein (13 patents)Arthur A OubrieArthur A Oubrie (9 patents)Sander De WildeSander De Wilde (4 patents)Eduard Willem ZwartEduard Willem Zwart (3 patents)Edwin De ZwartEdwin De Zwart (2 patents)Saskia VerkaikSaskia Verkaik (2 patents)Dennis DemontDennis Demont (2 patents)Carsten Schultz-FademrechtCarsten Schultz-Fademrecht (6 patents)Carsten Schultz-FadermrechtCarsten Schultz-Fadermrecht (1 patent)Carsten Schultz - FademrechtCarsten Schultz - Fademrecht (0 patent)Tjeerd Andries BarfTjeerd Andries Barf (0 patent)Sander Martijn De WildeSander Martijn De Wilde (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Merck Sharp + Dohme B.v. (2 from 55 patents)

2. Acerta Pharma B.v. (2 from 21 patents)


4 patents:

1. 11110088 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase

2. 10736893 - Imidazopyrazine inhibitors of Bruton's tyrosine kinase

3. 9102676 - MK2 inhibitors

4. 8772286 - MK2 inhibitors

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/8/2026
Loading…